Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEA peptide + ErbB2 peptide + MUC1 peptide
- Development stage
- Unknown
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intramuscular
01
Overview
A peptide-based cancer vaccine consisting of three tumor-associated antigen (TAA) peptides: CEA (carcinoembryonic antigen), ErbB2 (also known as HER2/neu), and MUC1 (mucin 1). This combination vaccine is designed to induce specific immune responses against cancer cells expressing these antigens. The vaccine works by stimulating CD8+ T cells and natural killer (NK) cells to recognize and kill cancer cells. The MUC1 peptide is included in all formulations of this vaccine, while CEA and ErbB2 peptides may be added based on immunohistochemical staining of the patient's tumor. This approach represents a consolidation treatment strategy for patients with breast and ovarian cancers who have completed standard treatments and are in clinical disease remission.
- Other names
- Triple peptide vaccine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)MUC1 (Mucin-1 Antigen)TCR-pHLA-A2 (T-cell receptor recognizing peptide-HLA-A2 complex)
Beyond the preview
Go deeper on CEA peptide + ErbB2 peptide + MUC1 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEA peptide + ErbB2 peptide + MUC1 peptide.